Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

ESMO Open

article

S.P. D¹  S. Bhatia³  A.S. Brohl⁴  O. Hamid⁵  J.M. Mehnert⁶  P. Terheyden⁷  K.C. Shih⁸  I. Brownell^1,10  C. Lebbé^1,11  K.D. Lewis^1,13  G.P. Linette^1,14  M. Milella^1,15  H. Xiong^1,16  G. Guezel^1,17  P.T. Nghiem^1,18 

[1] Department of Medicine, Memorial Sloan Kettering Cancer Center;Department of Medicine, Weill Cornell Medical College;Department of Medicine, University of Washington Medical Center;Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center;Department of Medical Oncology, The Angeles Clinic and Research Institute;Division of Medical Oncology, Rutgers Cancer Institute of New Jersey;Department of Dermatology, University of Lübeck;Department of Medical Oncology, Sarah Cannon Research Institute;Department of Medical Oncology;Dermatology Branch, National Institutes of Health;Université de Paris;Dermatology and CIC, AP-HP, Saint Louis Hospital;Department of Medicine, University of Colorado Denver School of Medicine;Center for Cellular Immunotherapies, University of Pennsylvania;Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust;Biostatistics, EMD Serono Research & Development Institute, Inc.;Clinical Development, Merck Healthcare KGaA;Division of Dermatology, Department of Medicine, University of Washington Medical Center at South Lake Union

关键词: Merkel cell carcinoma;    avelumab;    immunotherapy;    overall survival;   

DOI  :  10.1016/j.esmoop.2021.100290

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background 5 years of follow-up from the cohort of patients with mMCC whose disease had progressed after one or more prior lines of chemotherapy.Patients and methods In Part A of the single-arm, open-label, phase II JAVELIN Merkel 200 trial, patients with mMCC that had progressed following one or more prior lines of chemotherapy received avelumab 10 mg/kg by intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. In this analysis, long-term OS was analyzed.Results In total, 88 patients were treated with avelumab. At data cut-off (25 September 2020), median follow-up was 65.1 months (range 60.8-74.1 months). One patient (1.1%) remained on treatment, and an additional patient (1.1%) had reinitiated avelumab after previously discontinuing treatment. Median OS was 12.6 months [95% confidence interval (CI) 7.5-17.1 months], with a 5-year OS rate of 26% (95% CI 17% to 36%). In patients with PD-L1+ versus PD-L1− tumors, median OS was 12.9 months (95% CI 8.7-29.6 months) versus 7.3 months (95% CI 3.4-14.0 months), and the 5-year OS rate was 28% (95% CI 17% to 40%) versus 19% (95% CI 5% to 40%), respectively (HR 0.67; 95% CI 0.36-1.25).Conclusion Avelumab monotherapy resulted in meaningful long-term OS in patients with mMCC whose disease had progressed following chemotherapy. These results further support the role of avelumab as a standard of care for patients with mMCC.

【 授权许可】

CC BY|CC BY-NC-ND